Evidence map›Paper›PMID 42165594›Full record

ArticleJournal of virology2026

Establishment of an oral enterovirus 71 (EV71) infection model in immunocompetent mice for antiviral therapy evaluation.

Yisha Ma, Dan Luo, Xianliang Ke, Xiaohui Song, Mengchan Hao, Jianjun Chen, Yuan Zhang

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yisha MaState Key Laboratory of Virology and Biosafety, Chinese Academy of Sciences Wuhan Institute of Virology, Wuhan, People's Republic of China.ORCID 0009-0006-4188-0595
Dan LuoDepartment of Gastroenterology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Xianliang KeState Key Laboratory of Virology and Biosafety, Chinese Academy of Sciences Wuhan Institute of Virology, Wuhan, People's Republic of China.
Xiaohui SongDepartment of Obstetrics, Wuhan Children's Hospital, Wuhan Maternal and Child Healthcare Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Mengchan HaoState Key Laboratory of Virology and Biosafety, Chinese Academy of Sciences Wuhan Institute of Virology, Wuhan, People's Republic of China.
Jianjun ChenState Key Laboratory of Virology and Biosafety, Chinese Academy of Sciences Wuhan Institute of Virology, Wuhan, People's Republic of China.ORCID 0000-0002-2966-2388
Yuan ZhangState Key Laboratory of Virology and Biosafety, Chinese Academy of Sciences Wuhan Institute of Virology, Wuhan, People's Republic of China.ORCID 0000-0003-2444-7766

Funding

National Natural Science Foundation of China 32270180Natural Science Foundation of Hubei Province 2022CFB442Wuhan Medical Research Project WX21C06
6 · The paper itself

Abstract

Enterovirus 71 (EV71) is one of the major pathogens responsible for hand-foot-and-mouth disease in children and is associated with severe neurological complications, including death. Despite the fact that EV71 naturally infects humans through the oral route, the absence of a simple and reliable oral infection model has significantly impeded investigations into its pathogenesis and the development of antiviral interventions. In this study, we established a robust oral EV71 infection model in widely used immunocompetent BALB/c mice, employing a clinical isolate devoid of adaptive mutations. Mice infected via the oral route developed disease progression and clinical, as well as pathological features that closely recapitulate those observed in human infection. We further identified marked differences in viral dissemination and host immune responses between oral and intraperitoneal inoculation, underscoring the importance of physiologically relevant oral infection models for elucidating EV71 pathogenesis. In addition, the anti-EV71 candidate drug rupintrivir showed reduced efficacy in the oral infection model compared with the intraperitoneal model. Notably, this oral model enables evaluation of therapies designed to block intestinal viral infection-a capability lacking in intraperitoneal models. Using this platform, we assessed an intestinal probiotic blockade therapy for the first time. Our findings demonstrate that the probiotic formulation effectively suppresses viral replication and alleviates pathological damage in the spleen, lungs, kidneys, and other organs, providing a scientific basis for developing probiotic-based therapeutic strategies against viral infections. IMPORTANCE: The restricted host tropism of enterovirus 71 (EV71) has limited the development of animal models that accurately recapitulate human disease. Here, we demonstrate for the first time that the clinically isolated EV71-GZCII strain successfully infects 14-day-old immunocompetent BALB/c mice via oral gavage, establishing a physiologically relevant model that addresses this critical gap. Orally infected mice displayed distinct viral dissemination patterns and host immune responses compared with intraperitoneal models, highlighting the critical role of infection route in EV71 pathogenesis. Using this system, we evaluated the

Indexed as

Antiviral AgentsDisease Models, AnimalEnterovirus A, HumanEnterovirus InfectionsHand, Foot and Mouth DiseaseAdministration, OralAnimalsFemaleHumansImmunocompetenceMiceMice, Inbred BALB CProbioticsVirus ReplicationAntiviral Agentsantiviral drugsEV71immune responseimmunocompetent miceintestinal probiotic blockade therapyoral infectionvirus transmission in vivo

Identifiers

PMID42165594
PMCPMC13288771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.